ArticleScientific reports2022
Effects of immune-mediated inflammatory diseases on cardiovascular diseases in patients with type 2 diabetes: a nationwide population-based study.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Cardiovascular risk in axial spondyloarthritis-a systematic review.Clinical rheumatology · 2023Pooled it
- Association between inflammatory bowel disease and risk of stroke: a systematic review and meta-analysis of cohort studies.Frontiers in neurology · 2023Pooled it
- Glucagon-like peptide 1 analogues in patients with inflammatory bowel disease with metabolic disorders: More than weight loss?Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Article
- Cardiovascular involvement in ankylosing spondylitis and axial spondyloarthritis: epidemiology, mechanisms, and clinical management.Frontiers in medicine · 2026Review
- Diabetes is associated with a poor prognosis in patients with psoriasis and coronary artery disease.BMC endocrine disorders · 2025Article
- Sex differences in the risk of incident systemic sclerosis: a nationwide population-based study with subgroup analyses.Scientific reports · 2025Article
- Cardiovascular risk according to biological agent exposure in patients with ankylosing spondylitis: a nationwide population-based study.Clinical rheumatology · 2025Article
- Autoimmune inflammation as a key risk factor for heart failure with preserved ejection fraction: the different types of inflammation driving to HFpEF.Frontiers in medicine · 2025Review
- Epidemiologic Trends and Socioeconomic Disparities of Ankylosing Spondylitis in South Korea: A Nationwide Population-Based Study, 2010-2021.Yonsei medical journal · 2024Article
- Incidence rate of recurrent cardiovascular events in patients with radiographic axial spondyloarthritis and the effect of tumor necrosis factor inhibitors.Arthritis research & therapy · 2024Article
- Association of ankylosing spondylitis with cardiovascular disease: a bidirectional two-sample mendelian randomization study.Frontiers in genetics · 2024Article
- Higher gamma-glutamyl transferase levels are associated with an increased risk of incident systemic sclerosis: a nationwide population-based study.Scientific reports · 2023Article
- Risk of kidney failure in patients with systemic sclerosis: a nationwide population-based study.RMD open · 2023Article
- Lipoprotein(a) is a new prognostic factor in patients with psoriasis and coronary artery disease: a retrospective cohort study.Lipids in health and disease · 2023Article
- Systemic sclerosis is a risk factor of incident psoriasis: results from a nationwide cohort study.Frontiers in immunology · 2023Article
- Association of immune-mediated inflammatory diseases with depression and anxiety in patients with type 2 diabetes: A nationwide population-based study.Frontiers in medicine · 2023Article
- Risk of all-cause and cause-specific mortality associated with immune-mediated inflammatory diseases in Korea.Frontiers in medicine · 2023Article
- Association Between Lipid Profile and Risk of Incident Systemic Sclerosis: A Nationwide Population-Based Study.Clinical epidemiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Both type 2 diabetes and immune-mediated inflammatory diseases (IMIDs), such as Crohn's disease (CD), ulcerative colitis, rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriasis (PsO) are risk factors of cardiovascular disease. Whether presence of IMIDs in patients with type 2 diabetes increases their cardiovascular risk remains unclear. We aimed to investigate the risk of cardiovascular morbidity and mortality in patients with type 2 diabetes and IMIDs. Patients with type 2 diabetes without cardiovascular disease were retrospectively enrolled from nationwide data provided by the Korean National Health Insurance Service. The primary outcome was cardiovascular mortality, and the secondary outcomes were myocardial infarction (MI), stroke, and all-cause mortality. Inverse probability of treatment weighting (IPTW)-adjusted Cox proportional hazard regression analysis was performed to estimate the hazard ratios (HRs) and 95% confidence intervals (95% CIs) for each IMID. Overall 2,263,853 patients with type 2 diabetes were analyzed. CD was associated with a significantly higher risk of stroke (IPTW-adjusted HR: 1.877 [95%CI 1.046, 3.367]). UC was associated with a significantly higher risk of MI (1.462 [1.051, 2.032]). RA was associated with a significantly higher risk of cardiovascular mortality (2.156 [1.769, 2.627]), MI (1.958 [1.683, 2.278]), stroke (1.605 [1.396, 1.845]), and all-cause mortality (2.013 [1.849, 2.192]). AS was associated with a significantly higher risk of MI (1.624 [1.164, 2.266]), stroke (2.266 [1.782, 2.882]), and all-cause mortality (1.344 [1.089, 1.658]). PsO was associated with a significantly higher risk of MI (1.146 [1.055, 1.246]), stroke (1.123 [1.046, 1.205]) and all-cause mortality (1.115 [1.062, 1.171]). In patients with type 2 diabetes, concomitant IMIDs increase the risk of cardiovascular morbidity and mortality. Vigilant surveillance for cardiovascular disease is needed in patients with type 2 diabetes and IMIDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.